Novel systemic markers for patients with Alzheimer disease? - A pilot study

Current Alzheimer Research

Volumn 5, Issue 4, 2008, Pages 358-366

  Kassner, Stefan S ^a   Bonaterra, Gabriel A ^a   Kaiser, Elmar ^a   Hildebrandt, Wulf ^b   Metz, Jürgen ^a   Schröder, Johannes ^a   Kinscherf, Ralf ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Alzheimer; Inflammation; oxLDL; PBMC

Indexed keywords

BETA SECRETASE; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; CD38 ANTIGEN; CD40 ANTIGEN; CYCLOOXYGENASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PRESENILIN 1; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MALE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIGENS, CD38; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPIDS; LIPOPROTEINS, LDL; MALE; PILOT PROJECTS; POLY(ADP-RIBOSE) POLYMERASES; PRESENILIN-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48749090016     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508785132253     Document Type: Article

References (51)

1. Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol 64: 743-53 (2005).
2. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101: 2173-8 (2004).
3. Flirski M and Sobow T. Biochemical markers and risk factors of Alzheimer's disease. Curr Alzheimer Res 2: 47-64 (2005).
4. Roth AD, Ramirez G, Alarcon R, von Bernhardi R. Oligodendrocytes damage in Alzheimer's disease: Beta amyloid toxicity and inflammation. Biol Res 38: 381-387 (2005).
5. McGeer PL and McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22: 799-809 (2001).
6. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12: 1005-15 (2006).
7. Combs CK, Johnson DE, Karlo JC. Cannady S.B. Landreth G.E. Inflammatory Proinflammatory Responses and Neurotoxicity by PPAR Agonists. J Neurosci 20: 558-567 (2000).
8. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 61: 668-72 (2004).
9. Bergman M, Salman H, Beloosesky Y, Djaldetti M, Bessler H. Are peripheral blood cells from patients with Alzheimer disease more sensitive to apoptotic stimuli? Alzheimer Dis Assoc Disord 16: 156-60 (2002).
10. Dorszewska J, Florczak J, Rozycka A, Jaroszewska-Kolecka J, Trzeciak WH, Kozubski W. Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease. DNA Cell Biol 24: 786-94 (2005).
11. Zhang L, Song L, Terracina G, Liu Y, Pramanik B, Parker E. Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides. Biochemistry 40: 5049-55 (2001).
12. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, et al. Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-β Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase. J Neurosci 23: 9796-9804 (2003).
13. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 103: 443-8 (2006).
14. Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Disord 16: 136-44 (2003).
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health an human services task force on Alzheimer's disease. Neurology 34: 939-965 (1984).
16. Kaiser E, Schönknecht P, Thomann PA, Hunt A, Schröder J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci Lett 417: 193-195 (2007).
17. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke 14: 399-401 (1983).
18. Mancuso C, Scapagini G, Currò D, Giuffrida Stella AM, De Marco C, Butterfield DA, et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 12: 1107-23 (2007).
19. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17: 14-20 (1998).
20. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 56: 1683-1989 (2001).
21. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J Neurosci Res 72: 141-6 (2003).
22. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398: 466-7 (1999).
23. Kirsch C, Eckert GP, Koudinov AR, Müller WE. Brain cholesterol, statins and alzheimer's disease. Pharmacopsychiatry 36 (Suppl 2): S113-9 (2003).
24. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Cruz-Sanchez FF, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61: 199-205 (2003).
25. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman D.A. Statins and the risk of dementia. Lancet 356: 1627-31 (2000).
26. Rockwood K, Kirkland S, Hogan DB, McKnight C, Merry H, Verreault R, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59: 223-7 (2002).
27. Schönknecht P, Lütjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, et al. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 324: 83-5 (2002).
28. Zhang Q, Powers ET, Nieva J, Huff ME, Dendle MA, Bieschke J, et al. Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci USA 101: 4752-7 (2004).
29. Draczynska-Lusiak B, Doung A, Sun AY. Oxidized lipoproteins may play a role in neuronal cell death in Alzheimer disease. Mol Chem Neuropathol 33: 139-48 (1998).
30. Jovinge S, Ares MP, Kallin B, Nilsson J. Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Arterioscler Thromb Vasc Biol 16: 1573-9 (1996).
31. Luo Y, Liang C, Xu C, Jia Q, Huang D, Chen L, et al. Ciglitazone inhibits oxidized-low density li poprotein induced immune maturation of dendritic cells. J Cardiovasc Pharmacol 44: 381-385 (2004).
32. Finch CE and Morgan TE. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res 4: 185-9 (2007).
33. Bodnar RJ, Pasternak GW, Mann PE, Paul D, Warren R, Donner DB. Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Cancer Res 49: 6280-4 (1989).
34. Tracey KJ and Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann Rev Med 45: 491-503 (1994).
35. Sternberg EM. Neural-immune interactions in health and disease. J Clin Invest 100: 2641-2647 (1997).
36. Ibrahim S, Jilani I, O'Brien S, Rogers A, Manshouri T, Giles F, et al. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer 97: 1914-9 (2003).
37. Kalinowska A and Losy J. PECAM-1, a key player in neuroinflammation. Eur J Neurol 13: 1284-90 (2006).
38. Musso T, Deaglio S, Franco L, Calosso L, Badolato R, Garbarino G, et al. CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. J Leukoc Biol 69: 605-12 (2001).
39. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 178: 449-460 (1993).
40. Morra M, Zubiaur M, Terhorst C, Sancho J, Malavasi F. CD38 is functionally dependent on the TCR/CD3 complex in human T cells. FASEB J 12: 581-592 (1998).
41. Maat-Schieman ML, van Duinen SG, Rozemuller AJ, Haan J, Roos RA. Association of vascular amyloid beta and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease. J Neuropathol Exp Neurol 56: 273-84 (1997).
42. Uchihara T, Akiyama H, Kondo H, Ikeda K. Activated microglial cells are colocalized with perivascular deposits of amyloid-beta protein in Alzheimer's disease brain. Stroke 28: 1948-50 (1997).
43. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239: 290-2 (1988).
44. Eglitis MA and Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci USA 94(8): 4080-5 (1997).
45. Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, et al. beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol 279: C1772-81 (2000).
46. Giri R, Selvaraj S, Miller CA, Hofman F, Yan SD, Stern D, et al. Effect of endothelial cell polarity on beta-amyloid-induced migration of monocytes across normal and AD endothelium. Am J Physiol 283: C895-904 (2002).
47. Schindowski K, Kratzsch T, Peters J, Steiner B, Leutner S, Touchet N, et al. Impact of aging: sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer's disease. Neuromol Med 4: 161 -78 (2003).
48. Pluta R. Role of ischemic blood-brain barrier on amyloid plaques development in Alzheimer's disease brain. Curr Neurovasc Res 4: 121-9 (2007).
49. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, et al. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170: 680-92 (2007).
50. Satoh J, Kuroda Y. Constitutive and cytokine-regulated expression of presenilin-1 and presenilin-2 genes in human neural cell lines. Neuropathol Appl Neurobiol 25: 492-503 (1999).
51. Liao YF, Wang BJ, Cheng HT, Kuo LH, Wolfe MS. Tumor necrosis factor-alpha, interleukin-1 beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem 279: 49523-32 (2004).